Conference

 
 

Our agenda is carefully curated by an experienced team who are plugged into a global network.

Our presenters are disruptors and visionary industry leaders from the biopharma industry. They are selected for their relevance, dynamism and insight.

Online, 4 - 6 May 2021

Schedule

Create your personal agenda –check the favourite icon

May 409:00
Conference pass
May 409:10
Conference pass

Safety, efficacy, and uptake of currently available COVID-19 vaccines

Keynotes
Moderator: Jakob Cramer, Head Of Clinical Development, CEPI
Randall Hyer, Head of Medical Affairs, Moderna Therapeutics
Andrew Pollard, Director, Oxford Vaccine Group
Gregory Glenn, President, Research And Development, Novavax
Antonio Gonzalez Lopez, Global Clinical Head, Astrazeneca
May 411:00
Conference pass

From science to solidarity: the successes and limits of the global COVID-19 vaccine response

Keynotes
Soumya Swaminathan, Chief Scientist, World Health Organisation
May 411:30
Conference pass

HEALTH AS A GLOBAL IMPERATIVE: From COVID-19 to a New Normal for Vaccines & Pandemic Preparedness

Keynotes
Trevor Mundel, President, Global Health, The Bill & Melinda Gates Foundation
May 413:00
Conference pass

Operationalisation of large clinical trials mid pandemic.

Clinical Trials & Development
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, ICON Clinical Research Limited
Dinah Knotts-Keeterle, Sr. Director, Project Management, ICON plc
May 413:00
Conference pass

Integrated Technology Solutions for Vaccine Development

Vaccine Bioprocess & Manufacturing
Ronald Soriano, Field Application Scientist, Malvern Panalytical
May 413:00
Conference pass

Panel: Future perspectives for combination immunotherapies

Cancer Immunotherapy
·What class of combination therapies are most promising? What do the current data tell us?o Conventional Therapy e.g., Chemo/ radiationo Antibody Drug Conjugateso Angiogenesis inhibitors and other targeted therapieso IO/IO combinationso Oncolytic viruses and cancer vaccines·Can precision medicine tools help with therapeutic selections?·Overcoming toxicities of combinations·Intratumoral approaches·Significant recent and upcoming phase III trials – will they boost the field or set us back?
May 413:15
Conference pass

Insights for Plasmid DNA Manufacturing in 2021

Vaccine Bioprocess & Manufacturing
May 413:30
Conference pass

Clinical supply and logistics

Clinical Trials & Development
May 413:30
Conference pass

One-stop-shop for production of conventional and next generation vaccines

Vaccine Bioprocess & Manufacturing
Sebastian Schuck, Director Global Business Development, Wacker Biotech
May 414:00
Conference pass

Russian efforts towards a COVID vaccine: EpiVacCorona

COVID-19: vaccine response & approaches
Presentations followed by Q&A
Rinat Maksyutov, Director General, The Vector State Research Center of Virology
May 414:00
Conference pass

Strong Partnership and Successful COVID-19 Vaccine Project Delivery

Clinical Trials & Development
Conor Knightly, VP, Clinical Operations, Infectious Disease, Moderna, Inc
May 414:00
Conference pass

Progress in the development of a personalized TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine for melanoma

Cancer Immunotherapy
May 414:15
Conference pass

Real-time Viral Titer Assay Capability Transforming Vaccine Production Processes

Vaccine Bioprocess & Manufacturing
James Robinson, Scientific Advisory Board LumaCyte & Vice Chair Scientific Advisory Board, CEPI
May 414:30
Conference pass

Title TBC

COVID-19: vaccine response & approaches
Raches Ella, Project Lead- SARS-CoV-2 Vaccine, Bharat Biotech
May 414:30
Conference pass

Clinical trials & safety evaluation of COVID-19 vaccines

Clinical Trials & Development
·Clinical safety in “Warp Speed” environmentoPre-licensureoChallenges CoPs, end points, placebo controlled trials (after first vaccines available)·Human challenge studies or other alternatives (after first vaccines available)·Clinical severity of Covid-19 infection in LMICs vs more developed countries·Clinical severity of Covid-19 vaccine break-through infectionin LMICs vs more developed countries·Role of DCMVs and IFPMA developers
May 414:30
Conference pass

mRNA Manufacturing: Removing Bottlenecks in PD and Manufacturing Process

Vaccine Bioprocess & Manufacturing
May 414:30
Conference pass

Clinical Development of GVAX for Pancreatic Cancer: cancer vaccine and shared antigens are coming back

Cancer Immunotherapy
May 415:00
Conference pass

Vaccine clinical update

COVID-19: vaccine response & approaches
Presentations followed by Q&A
May 415:00
Conference pass

Debottlenecking limitations in scaling up adherent cells by using Microcarrier Technology

Vaccine Bioprocess & Manufacturing
Heidi Trusheim, Head of Process Development, IDT Biologika
May 415:00
Conference pass

Adaptive T-cell immunotherapy for newly diagnosed glioblastoma: Using targeted antigen presentation to enhance immune responses

Cancer Immunotherapy
May 415:15
Conference pass

SARS-CoV-2 Vaccine Induced Antibody Profiles-Qualification of a multiplexed assay as a tool in the hunt for surrogates of protection

COVID-19: vaccine response & approaches
May 415:15
Conference pass

Successful Execution of a Phase 3 COVID-19 Vaccine Clinical Trial

Clinical Trials & Development
Zeil Rosenberg, Medical Director and Therapeutic Area Head- Vaccines, Accelerated Enrollment Solutions (AES)
May 415:15
Conference pass

Process development for vaccines using fixed-bed bioreactors: COVID-19 and VSV-vector vaccine case studies

Vaccine Bioprocess & Manufacturing
Pim Velthof, Senior Scientist, Batavia Biosciences
May 415:30
Conference pass

Virus-Like-Proteins

COVID-19: vaccine response & approaches
Gregory Glenn, President, Research And Development, Novavax
May 415:30
Conference pass

Large-Scale Production of Plasmid DNA and mRNA to Support Therapeutic & Vaccine Development

Clinical Trials & Development
May 415:30
Conference pass

Disrupting Cancer with SurVaxM immunotherapy: Development Updates

Cancer Immunotherapy
May 415:45
Conference pass

Recombinant COVID vaccine program

COVID-19: vaccine response & approaches
May 415:45
Conference pass

Panel: Using Abs and therapeutics to treat COVID and its potential to prevention in high-risk individuals

Clinical Trials & Development
Mark Esser, Senior Director, Vaccines And Infectious Diseases, Translational Medicine, MedImmune Inc
Nicholas Kartsonis, Senior Vice President Of Clinical Research, Infectious Diseases And Vaccines, Merck
David Weinreich, Executive Vice President, Head, Global Clinical Development, Regeneron Pharmaceuticals
Amanda Peppercorn, VP, Medicine Development Leader, COVID-19 mAb program, GSK
Ajay Nirula, Vice President, Immunology, Eli Lilly Research Laboratories
May 415:45
Conference pass

Rapid mRNA manufacturing for Vaccine Development

Vaccine Bioprocess & Manufacturing
Jessica Madigan, Associate Business Development Director, TriLink BioTechnologies
May 416:00
Conference pass

Janssen’s single dose COVID vaccine efforts and update program

COVID-19: vaccine response & approaches
May 416:00
Conference pass

Checkpoint inhibitor B-cell epitope vaccines: Unique design of PD-1, PD-L1 and LAG3 chimeric peptide combinations

Cancer Immunotherapy
May 416:15
Conference pass

Novel insights into T-cell responses to Covid-19

COVID-19: vaccine response & approaches
May 416:15
Conference pass

Cells in Motion: Teaming up Shakers and Bioprocess

Vaccine Bioprocess & Manufacturing
In this talk, we will depict the typical applications of shakers and bioreactors in an upscaling bioprocess. We will discuss the differences and factors that influence cultivation and system transition. Furthermore, we will introduce to you the basic components of a bioreactor and the various process parameters that can be controlled.
Rodrigo Ribeiro, Marketing Manager, Eppendorf Inc.
May 416:30
Conference pass

Dyadic C1-Cells - Flexible Scale Manufacturing of NexGen MonoValent & MultiValent Recombinant Antigen Vaccines & Antibodies

COVID-19: vaccine response & approaches
May 416:30
Conference pass

Increasing vaccine production using Viral Sensitizer Technology

Vaccine Bioprocess & Manufacturing
Jean-Simon Diallo, Founder, Virica Biotech
May 416:45
Conference pass

Title TBC

COVID-19: vaccine response & approaches
Ted Hibben, CBO, Vaxess
May 416:45
Conference pass

Vaccine biosafety – how to ensure compliance with current and future global regulatory authority requirements

Clinical Trials & Development
May 416:45
Conference pass

ultraDAWN: Real-Time DSP Analytics Using Light Scattering

Vaccine Bioprocess & Manufacturing
Dan Some, Principal Scientist, Wyatt Technology
May 417:00
Conference pass

Vaxart oral covid-19 vaccine; hold the ice and the needles

COVID-19: vaccine response & approaches
May 417:00
Conference pass

New Tools for Next Generation Vaccine Development and QC

Vaccine Bioprocess & Manufacturing
Senior Representative, Bio-Rad
May 417:15
Conference pass

Altimmune’s Single Dose, Intranasal COVID-19 Vaccine Candidate, Prevents SARS-CoV2 induced Disease and Blocks Viral Replication In Preclinical Studies Of SARS-CoV-2 Infection

COVID-19: vaccine response & approaches
Dr. Sarah Browne, Senior Director of Vaccine Development, Altimmune
Scot Roberts, Chief Scientific Officer, Altimmune
May 417:15
Conference pass

Developing a Global Informatics Framework In Preparation for Disease X

Clinical Trials & Development
May 417:15
Conference pass

Rapid tech transfer of vaccine products….best practices to start production quickly

Vaccine Bioprocess & Manufacturing

Create your personal agenda –check the favourite icon

May 509:00
Conference pass

Vaccine deployment and implementation – how do we deliver billions of vaccines globally?

Keynotes
-How COVID-19 Variants Could Change Timelines
Moderator: Jerome Kim, General Director, International Vaccine Institute
Christina Yi, Chief Operations Officer, COVAXX
Anuradha Gupta, Deputy Chief Executive Officer, GAVI
Kate O'Brien, Director, World Health Organisation
Jean-Cedric Meeus, Chief of Transport, UNICEF
May 510:30
Conference pass

Keynote panel: What of our second generation COVID-19 vaccines? Is SARS-CoV2 here to stay?

Keynotes
-How COVID-19 Variants Could Change Timelines
Moderator: Kayvon Modjarrad, Director, Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research
Andrew Pollard, Director, Oxford Vaccine Group
Tal Zaks, Chief Medical Officer, Moderna Therapeutics
Wayne Koff, President And Chief Executive Officer, The Human Vaccines Project
Dr FARSHAD GUIRAKHOO, CSO, GeoVax, Inc.
May 513:00
Conference pass

Mitigating the impact of covid-19 and future public health emergencies on oncology clinical trials

Cancer Immunotherapy
·The impact of the pandemic on sponsors dependent on CROs to run trials – how disruptive was it?·If trials are paused, how likely is it they will restart? What are the challenges in restarting paused trials·Contingency / business continuity plans for future pandemicsoUse of technology, what is the feasibility of telemedicine in oncology trials?oRemote monitoring for imagingoHow easy is it to set up use of alternative sites when travel restricted / use alternative vendors for imaging etc.·Development of analytics to account for dropoutsRegulatory considerations
Moderator: Andy Lee, Senior Vice President And Head Of Global Clinical Trial Operations, Merck
Kamran Ansari, SVP, Head of Clinical Development Operations, Seattle Genetics Inc
Simon J Trowell, Vice President of Clinical Development Quality and Risk Management, GlaxoSmithKline
May 513:00
Conference pass

Ph 3 results: CanSino’s Adenovirus-based Viral Vector Platform

COVID-19 trials & Infectious Diseases
May 513:00
Conference pass

Precision vaccinology: How is the field maturing?

Immune Profiling
- How good are we at targeting a vaccine to a specific population?- Evaluating and exploring vaccine responses in the elderly and very young- Autoimmunity: Determining the impact of COVID-19 mRNA vaccines in individuals with autoimmunity
David Dowling, Instructor In Pediatrics, Boston Children's Hospital
Petter Brodin, Assistant Professor of Immunology, Karolinska Institutet
Helder Nakaya, Associate Professor, School of Pharmaceutical Sciences, University Of Sao Paulo
May 513:00
Conference pass

Post-marketing safety challenges and considerations for new vaccines developed exclusively for LMICs

Vaccine Safety
May 513:25
Conference pass

Use of a geospatial visualization tool to track changes in coverage rates and disease incidence in rotavirus

Vaccine Safety
May 513:30
Conference pass

Clinical update of a plant-derived COVID VLP vaccine candidate

COVID-19 trials & Infectious Diseases
Dr. Brian J Ward, Professor at McGill University & Medical Officer, Medicago Inc
May 513:45
Conference pass

Dengue vaccine & enhanced dengue disease - understanding the impact of natural disease on vaccines

Vaccine Safety
Annelies Wilder-Smith, Professor of Emerging Infectious Diseases, LSHTM; Consultant, Initiative of Vaccine Research, WHO
May 514:00
Conference pass

An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth

Cancer Immunotherapy
May 514:00
Conference pass

Transformative Public / Private Partnership: Action with Urgency to Accelerate SARS-CoV-2 Vaccine Candidates’ Development

COVID-19 trials & Infectious Diseases
Luc Gagnon, VP Vaccine Sciences, Nexelis
Valentina Bernasconi, Scientist, CEPI
May 514:00
Conference pass

The new xMAP® INTELLIFLEX; A rich history of enabling groundbreaking research

Immune Profiling
Wilco de Jager, Senior Field Applications Scientist, Luminex B.V.
May 514:10
Conference pass

Joint Presentation: Cohort Event Monitoring (CEM) of Health Care Workers (HCW) receiving COVID19 vaccines using mobile apps in 5 LMICs

Vaccine Safety
May 514:30
Conference pass

Targeting ERAP1 to alter neoantigen presentation on the tumor cell surface, enabling greater immune recognition

Cancer Immunotherapy
May 514:30
Conference pass

Vaxchora® (Cholera Vaccine, Live, Oral) in Children and Adolescents

COVID-19 trials & Infectious Diseases
Mark Schneider, Sr. Dir Global Medical Affairs, Emergent BioSolutions
May 514:30
Conference pass

Highly Multiplexed Single-Cell Proteomics Identifies Key Inflammatory Mediators in Severe COVID-19

Immune Profiling
Victor Tek, Product Manager, IsoPlexis
May 514:40
Conference pass

Influenza & Narcolepsy case study - using genomics to inform vaccine safety

Vaccine Safety
May 515:00
Conference pass

Intradermal Vaccination – Cancer Vaccines

Cancer Immunotherapy
Dr John Vasilakos, Global Head of MTS Business Development & Senior Research Immunologist, Kindeva Drug Delivery
May 515:00
Conference pass

The critical role of private-public engagement in serving vaccine administration needs - Learning from COVID-19 pandemic

COVID-19 trials & Infectious Diseases
Senior representative, BD
Daniel Smith, Director US/Global Vaccination & Pandemic Preparedness, BD Medication Delivery Solutions
May 515:00
Conference pass

T-cell Immune Response: Exploring emerging themes in vaccine development and COVID-19 variants

Immune Profiling
Harlan Robins, CSO, Adaptive Biotechnologies
May 515:00
Conference pass

How has COVID-19 changed vaccine safety surveillance mechanisms?

Vaccine Safety
May 515:20
Conference pass

COVID-19 AESI List and Related Resources to Harmonize Safety Data Collection

Vaccine Safety
May 515:30
Conference pass

Pre-clinical to clincal development of RP1- a HSV-1-based virus expressing GALV-GP-R and GM-CSF

Cancer Immunotherapy
May 515:30
Conference pass

Pushing Boundaries: CEE Opportunities for Vaccine Trials

COVID-19 trials & Infectious Diseases
Senior representative, Pharm-Olam
Pavle Vukojevic, Chief Medical Officer, Pharm-Olam
Mila Shuvalova, Senior Medical Director, Pharm-Olam
May 515:30
Conference pass
May 515:45
Conference pass

Insights from near real time hospitalization data monitoring in the post COVID-19 vaccine period

Vaccine Safety
May 516:00
Conference pass

Updates in the clinical development of TG4001, a therapeutic vaccine combined with PD-L1 blockade for advanced HPV-positive cancers

Cancer Immunotherapy
May 516:00
Conference pass

PANEL: What impact does the new COVID-19 variants have on our timelines and preparation for other newly emerging viruses?

COVID-19 trials & Infectious Diseases
Sean Kirk, SVP, Emergent BioSolutions
Morgane Rolland, Chief, Viral Genetics Section, WRAIR
May 516:00
Conference pass

Title TBC

Immune Profiling
Senior Representative, 10X Genomics
May 516:00
Conference pass
May 516:30
Conference pass

Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

Cancer Immunotherapy
May 516:30
Conference pass

Profiling T cell responses to influenza vaccination at the single cell level

Immune Profiling
Richard Kennedy, Professor Of Medicine, Co-Director, Mayo Vaccine Research Group, Mayo Clinic
May 517:00
Conference pass

DYADIC C1-CELLS - Realizing Full Global Potential of MonoValent and/or MultiValent Recombinant Antigen Vaccines & Antibodies

COVID-19 trials & Infectious Diseases

Create your personal agenda –check the favourite icon

May 609:00
Conference pass

ROUNDTABLE: COVID-19 disease and vaccines for Adolescents and Pediatrics

Keynotes
Lynlee Burton, Executive Director Of Therapeutic Expertise - Vaccines, PRA Health Sciences
Jay Lieberman, Pediatrician and Infectious Di, PRA Health Sciences
May 609:00
Conference pass

ROUNDTABLE: COVID-19 Vaccine Clinical Development – Adjusting for a Changing Landscape

Keynotes
Ben Greener, Clinical Scientist Director, PPD
May 609:00
Conference pass

ROUNDTABLE: Diversity in clinical trials

Keynotes
Shelley Mclendon, Vice President, Vaccine and Infectious Disease, ICON Clinical Research Limited
Kelly Bauman, Sr. Director, Project Management Vaccines, ICON plc
May 609:00
Conference pass

ROUNDTABLE: Shifting the Clinical Trial Paradigm Utilizing Digital Approaches

Keynotes
The COVID19 pandemic has perpetuated the need to substantively modify the way clinical trial are conducted at study sites.Some of which sponsors and regulators would otherwise have never respectively embraced or permitted.This session will focus on the varied digital technologies available and extensively utilized during the window of opportunity we had to employ them.As the COVID19 pandemic forced us to shift our methods of study conduct from predominantly on-site and face-to-face to a more virtual milieu, perceived risks were quelled and benefits became apparent.We confirmed that through the use of relevant and appropriate technologies, digital trials could be conducted efficiently, economically, deliver high quality data, and enable expedited EUA of important new vaccines.What types of digital technologies have you used?Were they the right ones?What lessons did you learn?Come and share your digital clinical trial experiences and/or engage with those of us who have so you’re better prepared to utilize digital technologies as you conduct trials.
Tina Morgenstein, Project Director in the Vaccine Therapeutic Unit, PPD
May 610:00
Conference pass
May 610:10
Conference pass

Keynote Panel: Governance and strategy – how will the US tackle COVID-19 (and future pandemics) going forward?

Keynotes
Kayvon Modjarrad, Director, Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research
May 611:30
Conference pass

Keynote panel: Is the current vaccine business response to emerging infectious diseases unsustainable? How will big pharma, biotechs & research institutions work together in future?

Keynotes
Melanie Saville, Director Of Vaccine Development- Uk, CEPI
Dr David C Kaslow, Chief Scientific Officer, PATH
Maria Elena Bottazzi, Co-Director, Texas Children’s Hospital Center for Vaccine Development, Baylor College of Medicine
Jonathan Quick, Managing Director, Pandemic Response, Preparedness, and Prevention, The Rockefeller Foundation
May 614:00
Conference pass

Panel: Vaccinating against misinformation

Vaccine Safety
·Misinformation vs disinformation·Educating HCPs vs the public on misinformation·Tools to track misinformation in real-time and counter it·Major sources of vaccine disinformation·Global examples of social listening strategies·Role of stakeholders; public health orgs, government, industry
  • Amplifying vaccine advocacy voices – how can everyone be part of this?
May 614:00
Conference pass

Title TBC

COVID-19 Manufacture & Supply
Senior representative, IDT Biologika
May 614:00
Conference pass

Panel: Implications of COVID-19 for a healthy vaccines market

Market Access
· How has COVID-19 changed and shaped how we define a healthy vaccines market globally? · What can we learn from the policies and models that have driven or enabled innovation in COVID-19 vaccines? · What are we learning about distribution models for equitable access to COVID-19 vaccines? · Are these policies and models unique to pandemic response? What positive or negative unintended consequences may impact the short-, medium, and long-term health of the global vaccines market? · What are some distinct considerations for stakeholders at the national, regional, and global level who are driving vaccines markets in their respective geographies – looking beyond COVID-19 vaccines?
Moderator: Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, MSD
Jason Hall, Managing Director, Policy, Avalere Health LLC
Frederik Kristensen, Deputy Chief Executive Officer, Coalition For Epidemic Preparedness Innovations
May 614:00
Conference pass

Preparing for disease X

One Health & Veterinary Vaccines
Volker Gerdts, Director And Chief Executive Officer, VIDO-InterVac
May 614:15
Conference pass

Monitoring temperature to ensure vaccine efficacy during shipping, storage, and administration

COVID-19 Manufacture & Supply
Tony Fonk, CEO, SpotSee
May 614:30
Conference pass

Logistics, last-mile, and delivery of COVID-19 vaccines

COVID-19 Manufacture & Supply
May 614:30
Conference pass

Tackling SARS-CoV-2 in Animals

One Health & Veterinary Vaccines
Zoetis' COVID-19 vaccine
Mahesh Kumar, Senior VP, Global Biologics, Zoetis
May 615:00
Conference pass

Solutions in COVID-19 vaccine delivery

COVID-19 Manufacture & Supply
Senior representative, Aerosafe Global
May 615:00
Conference pass

Panel: Demonstrating the value of adult vaccination- improving uptake and access

Market Access
·Economic modeling- use in public health decision-making (CE and BIM)·Real World Evidence- demonstrating unmet need and disparities of care, assessing impact of policy decisions, testing interventions to improve coverage
Ray Farkouh, Senior Director Vaccines Market Access and HEOR, Pfizer
Sara Poston, Head of US Health Outcomes and Epidemiology, Vaccines, Glaxosmithkline
Craig Roberts, VP, Vaccines, Center for Observational and Real-World Evidence, Merck
May 615:00
Conference pass

Panel: How is the veterinary space tackling influenza viruses?

One Health & Veterinary Vaccines
Moderator: Cyril Gay, Senior National Program Leader, A.R.S. National Programs
Amy Richwine, Senior Director of Food Animal Vaccine Development, elanco animal health
Amy Vincent, Research Veterinary Medical Officer, United States Department of Agriculture
Richard J Webby, Director, World Health Organization Collaborating Centre for Studies on the Ecology of Influenza in Animals and Birds, St. Jude Children's Research Hospital
David Swayne, Laboratory Director, USDA
May 615:15
Conference pass

Progress of COVID-19 Vaccines with Needle-Free Delivery

COVID-19 Manufacture & Supply
May 615:30
Conference pass
May 615:30
Conference pass

Dyadic C1-Cells, industrially proven hyper productive thermophilic filamentous fungus for manufacturing safe, effective and affordable recombinant protein antigen vaccines & Antibodies for world popul

COVID-19 Manufacture & Supply
May 616:00
Conference pass

Panel: Sustainable vaccine manufacture

COVID-19 Manufacture & Supply
Moderated by CEPIAstraZenecaUniversity of OxfordSerum Institute of India GAVIFinal Panelists names to be announced shortly
May 616:00
Conference pass

Panel: mRNA vaccine tech emergence; Exploring the opportunities and challenges

One Health & Veterinary Vaccines
Sherry Layton, Chief Scientific Officer, Vetanco Sa
Channing Sebo, Diagnostic Analyst & Veterinarian, Merck Animal Health
Scott Holmstrom, Vice President, Product Development and Innovation Regulatory, elanco animal health
May 616:15
Conference pass

Presentation series: Immunosenescence as a high-risk immunocompromising condition for pneumococcal immunization recommendations:

Market Access
  1. Conceptual basis and implications for inclusion of immunosenescence as a high-risk condition
  2. Immunologic basis for immunosenescence contributing to pneumococcal disease risk
  3. Epidemiological basis for inclusion of immunosenescence as a high-risk condition
May 617:00
Conference pass

Plenary Take Home Remarks – Until We Meet Again

Keynotes
last published: 19/Apr/21 18:25 GMT